跳至主要内容
临床试验/NCT02496377
NCT02496377已完成不适用

Comparison of Preoperative Haemoglobin Level After Administration of Epoetin Alfa Associated With an Oral Versus Intravenous Iron Supplementation

University Hospital, Montpellier1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年8月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
1
主要终点
Compare Hb level after treatment with EPO associated with iron treatment by oral or intravenous route

研究概览

简要总结

Patients were recruited at the scheduled preoperative visit for hip or knee arthroplasty. If the haemoglobin (Hb) level was below 13 g/dl with no contraindication to iron supplementation the patients were randomized to the oral or intravenous (IV) group. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7). The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections. Primary efficacy endpoint was the change in Hb level from the day of the preoperative visit to the day before surgery (day-1). Secondary endpoints comprised the Hb level on day 3 and 5 after surgery, allogenic transfusion during and after surgery, and the change in iron indices from the day of the preoperative visit to day - 1.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Group 1: Per Os Tardyferon

Active Comparator

EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).

干预措施: ferrous glycine sulfate Tardyferon (Drug)

Group 1: Per Os Tardyferon

Active Comparator

EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).

干预措施: Epoetin Alfa (Drug)

Group 2: IV Ferinject

Experimental

EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.

干预措施: Epoetin Alfa (Drug)

Group 2: IV Ferinject

Experimental

EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.

干预措施: ferric carboxymaltose Ferinject (Drug)

结局指标

主要结局

Compare Hb level after treatment with EPO associated with iron treatment by oral or intravenous route

时间窗: the day before surgery (day - 1)

次要结局

  • Hb level(before iron treatment, then the day before surgery (day - 1) based on reference iron balance)
  • number of red blood cells(during surgery and 3 days after surgery)
  • the change in iron indices(before iron treatment and after iron treatment the day before surgery (day - 1))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验